Recent Updates
Recently added Catalysts
ALKS

Relevant slides from Alkermes plc's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on

Tuesday, January 9, 2018 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Relevant slides from Alkermes plc's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on January 9, 2018:

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

Relevant slides from Alkermes plc's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on January 9, 2018:
ShareAdd on Google
Tags: ALKS Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 9, 2018

Biotech snapshot

Cash runway
$691M liquidity · $0M/mo burn
Low dilution risk
Lead asset
N1539Phase 2
Hysterectomy →

Catalyst track record

+29%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →